366 related articles for article (PubMed ID: 28253902)
1. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
[TBL] [Abstract][Full Text] [Related]
2. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T
Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246
[TBL] [Abstract][Full Text] [Related]
3. Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133
Song Y; Park IS; Kim J; Seo HR
Chem Biol Interact; 2019 Aug; 309():108713. PubMed ID: 31226288
[TBL] [Abstract][Full Text] [Related]
4. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
5. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
7. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma.
Ding K; Liao Y; Gong D; Zhao X; Ji W
Biochem Biophys Res Commun; 2018 Jul; 502(2):194-201. PubMed ID: 29800569
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133
Hemati H; Kaur J; Sobti RC; Trehanpati N
Biochem Biophys Res Commun; 2020 May; 525(4):941-947. PubMed ID: 32173531
[TBL] [Abstract][Full Text] [Related]
9. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
10. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
[TBL] [Abstract][Full Text] [Related]
11. Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines.
Yang J; Gong Y; Sontag DP; Corbin I; Minuk GY
Mol Biol Rep; 2018 Oct; 45(5):1023-1036. PubMed ID: 30069818
[TBL] [Abstract][Full Text] [Related]
12. Oxytetracycline have the therapeutic efficiency in CD133
Song Y; Kim IK; Choi I; Kim SH; Seo HR
Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
15. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma.
Guo W; Zhao Y; Zhang Z; Tan N; Zhao F; Ge C; Liang L; Jia D; Chen T; Yao M; Li J; He X
Cancer Lett; 2011 Dec; 312(1):55-61. PubMed ID: 21906871
[TBL] [Abstract][Full Text] [Related]
16. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation.
Hong SW; Hur W; Choi JE; Kim JH; Hwang D; Yoon SK
Oncotarget; 2016 Apr; 7(17):23482-97. PubMed ID: 26993601
[TBL] [Abstract][Full Text] [Related]
17. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133
Xu Y; Lai Y; Weng H; Tan L; Li Y; Chen G; Luo X; Ye Y
Aging (Albany NY); 2019 May; 11(9):2551-2564. PubMed ID: 31056532
[TBL] [Abstract][Full Text] [Related]
18. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
Zhang KZ; Zhang QB; Zhang QB; Sun HC; Ao JY; Chai ZT; Zhu XD; Lu L; Zhang YY; Bu Y; Kong LQ; Tang ZY
J Hematol Oncol; 2014 Mar; 7():28. PubMed ID: 24678763
[TBL] [Abstract][Full Text] [Related]
20. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
Cells; 2020 May; 9(5):. PubMed ID: 32408542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
